Multifunctional Analogs of Kynurenic Acid for the Treatment of Alzheimer’s Disease: Synthesis, Pharmacology, and Molecular Modeling Studies

• Published in: ACS chemical neuroscience Vol. 8; no. 12; pp. 2667 - 2675
• Main Authors: Deora, Girdhar Singh, Kantham, Srinivas, Chan, Stephen, Dighe, Satish N, Veliyath, Suresh K, McColl, Gawain, Parat, Marie-Odile, McGeary, Ross P, Ross, Benjamin P
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 20.12.2017
• Subjects: acetylcholinesterase inhibitor; antioxidant; Alzheimer’s disease; amyloid β peptide; mGluR5 antagonist; NMDAR antagonist
• ISSN: 1948-7193; 1948-7193
• DOI: 10.1021/acschemneuro.7b00229

We report the synthesis and pharmacological investigation of analogs of the endogenous molecule kynurenic acid (KYNA) as multifunctional agents for the treatment of Alzheimer’s disease (AD). Synthesized KYNA analogs were tested for their N-methyl-d-aspartate (NMDA) receptor binding, mGluR5 binding and function, acetylcholinesterase (AChE) inhibition, 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging, interference with the amyloid β peptide (Aβ) fibrillation process, and protection against Aβ-induced toxicity in transgenic Caenorhabditis elegans strain GMC101 expressing full-length Aβ42. Molecular modeling studies were also performed to predict the binding modes of most active compounds with NMDAR, mGluR5, and Aβ42. Among the synthesized analogs, 3c, 5b, and 5c emerged as multifunctional compounds that act via multiple anti-AD mechanisms including AChE inhibition, free radical scavenging, NMDA receptor binding, mGluR5 binding, inhibition of Aβ42 fibril formation, and disassembly of preformed Aβ42 fibrils. Interestingly, 5c showed protection against Aβ42-induced toxicity in transgenic C. elegans strain GMC101. Moreover, 5b and 5c displayed high permeability in an MDR1-MDCKII cell-based model of the blood–brain barrier (BBB). Compound 3b emerged with specific activity as a micromolar AChE inhibitor, however it had low permeability in the BBB model. This study highlights the opportunities that exist to develop analogs of endogenous molecules from the kynurenine pathway for therapeutic uses.